文献速递胸部肿瘤

motesanib联合紫杉醇卡铂治疗东亚非鳞非小细胞肺癌的III期随机双盲安慰剂对照试验

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2017-09-13

这项III期随机双盲安慰剂对照试验在东亚晚期非鳞非小细胞肺癌患者中比较motesanib联合紫杉醇卡铂与安慰剂联合紫杉醇卡铂。motesanib组197例、安慰剂组204例,中位无进展生存期6.1个月对5.6个月(分层HR 0.81,95%CI 0.64~1.03,P=0.0820),差异未达统计学显著;motesanib组≥3级不良事件和导致停药的不良事件更多。

要点

  • motesanib联合紫杉醇卡铂较安慰剂联合方案未显著改善无进展生存期
  • motesanib组≥3级不良事件86.7%、导致停药的不良事件32.7%,均高于安慰剂组
  • motesanib组客观缓解率60.1%高于安慰剂组41.6%(P<0.001)

核心结论

  • 在东亚Ⅳ期/复发非鳞非小细胞肺癌患者中,motesanib联合紫杉醇卡铂较安慰剂联合紫杉醇卡铂未显著改善无进展生存期。

研究设计与样本

  • III期随机、安慰剂对照、双盲研究,按1:1随机分为motesanib 125 mg口服每日一次联合紫杉醇200 mg/m2静脉给药及卡铂曲线下面积6 mg/mL·min静脉给药(最多6个3周周期)组197例与安慰剂联合紫杉醇卡铂组204例,共401例。
  • 随机分层因素为表皮生长因子受体状态、地区和随机分组前6个月内体重下降。

主要发现

  • 中位无进展生存期motesanib组6.1个月对安慰剂组5.6个月(分层log-rank检验P=0.0825;分层风险比0.81;95%CI 0.64~1.03;P=0.0820)。
  • 中位总生存期motesanib组未达到,安慰剂组21.6个月(P=0.5514)。
  • 客观缓解率motesanib组60.1%对安慰剂组41.6%(P<0.001);中位至肿瘤缓解时间1.4个月对1.6个月;中位缓解持续时间5.3个月对4.1个月。
  • ≥3级不良事件发生率motesanib组86.7%对安慰剂组67.6%;导致停药的不良事件发生率32.7%对14.2%。
  • motesanib组更常见的不良事件为胃肠道疾病、高血压和胆囊相关不良事件。

关键数值与推荐

  • 主要终点为无进展生存期,关键次要终点为总生存期,其他次要终点包括客观缓解率、至肿瘤缓解时间、缓解持续时间和不良事件。
  • motesanib用法为口服125 mg每日一次,联合紫杉醇200 mg/m2静脉给药及卡铂曲线下面积6 mg/mL·min静脉给药,最多6个3周周期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose This phase III, randomized, placebo-controlled, double-blind study determined whether motesanib improved progression-free survival (PFS) compared with placebo in combination with paclitaxel and carboplatin (P/C) in East Asian patients with stage IV/recurrent nonsquamous non-small-cell lung cancer. Patients and Methods Patients were randomly assigned (1:1) to receive oral motesanib 125 mg or placebo once daily plus paclitaxel 200 mg/m2 IV and carboplatin area under the concentration-time curve 6 mg/mL ⋅ min IV for up to six 3-week cycles. Random assignment was stratified by epidermal growth factor receptor status, region, and weight loss in the 6 months before assignment. The primary end point was PFS, the key secondary end point was overall survival, and other secondary end points were objective response rate, time to tumor response, duration of response, and adverse events (AEs). Results Four hundred one patients were assigned to receive motesanib plus P/C (n = 197) or placebo plus P/C (n = 204). Median PFS was 6.1 v 5.6 months for motesanib versus placebo (stratified log-rank test P = .0825; stratified hazard ratio, 0.81; 95% CI, 0.64 to 1.03; P = .0820); median overall survival was not reached versus 21.6 months ( P = .5514). In secondary analyses, the objective response rate was 60.1% v 41.6% ( P < .001); median time to tumor response, 1.4 v 1.6 months, and median duration of response, 5.3 v 4.1 months. Incidence of grade ≥ 3 AEs (86.7% v 67.6%) and AEs that led to drug discontinuation (32.7% v 14.2%) were higher with motesanib than with placebo. AEs reported more frequently with motesanib were GI disorders, hypertension, and gallbladder related. Conclusion Motesanib plus P/C did not significantly improve PFS versus placebo plus P/C in East Asian patients with stage IV/recurrent nonsquamous non-small-cell lung cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kubota K, Yoshioka H, Oshita F, et al. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017. PMID: 28902534. doi:10.1200/JCO.2017.72.7297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。